# US 2021/0171958 A1 · Methods of treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171958 A1
- Document ID: US20210171958A1
- Status: Published application
- Kind: A1
- Application number: 17/270,170
- Filed: 2019-08-23
- Published: 2021-06-10
- Earliest claimed: 2018-08-23
- Assignees: Foghorn Therapeutics Inc.
- Applicants: Foghorn Therapeutics Inc.
- Inventors: Ho Man CHAN; Qianhe ZHOU; Luis SOARES
- Web page: https://patentgrep.com/patent/US20210171958A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12N 9/14: Hydrolases (3)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12Y 306/04012: DNA helicase (3.6.4.12)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present disclosure features useful methods to treat cancer having a deficiency in ARID1 A and/or mismatch repair deficiency, e.g., in a subject in need thereof. In some embodiments, the methods described herein are useful in the treatment of cancer in combination with immunotherapies.

## Claims

### Claim 1

A method of treating cancer having a mutation that results in a loss of function of AT-Rich Interaction Domain 1A (ARID1A) in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of Werner Syndrome RecQ Like Helicase (WRN) in a cell in the subject.

### Claim 2

A method of reducing the level and/or activity of WRN in a cancer cell having a mutation that results in a loss of function of ARID1A in a subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of WRN in the cell.

### Claim 3

A method of reducing tumor growth of a cancer having a mutation that results in a loss of function of ARID1A in a subject, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of WRN in a cell in the subject.

### Claim 4

A method of treating cancer having a mismatch repair deficiency (MMRd) in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of WRN in a cell in the subject.

### Claim 5

A method of reducing the level and/or activity of WRN in a cancer cell having a MMRd in a subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of WRN in the cell.

### Claim 6

A method of reducing tumor growth of a cancer having a MMRd in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of WRN in a cell in the subject.

### Claim 7

A method of treating cancer having a microsatellite instability (MSI)-positive phenotype in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of WRN in a cell in the subject.

### Claim 8

A method of reducing the level and/or activity of WRN in cancer cell having an MSI-positive phenotype in a subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of WRN in the cell.

### Claim 9

A method of reducing tumor growth of a cancer having an MSI-positive phenotype in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of WRN in a cell in the subject.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the activity of WRN is WRN helicase activity.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 4-10, wherein the MMRd is associated with a mutation in the MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, PMS2, and/or EPCAM genes.

### Claim 12 (depends on 11)

The method of claim 11, wherein the MMRd is associated with a mutation in the MLH1, MSH2, MSH6, PMS2, and/or EPCAM genes.

### Claim 13 (depends on 12)

The method of claim 12, wherein the MMRd is associated with a mutation in the MLH1 gene.

### Claim 14 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 4-13, wherein the cancer has an MSI-positive phenotype characterized by the presence of an MSI at least one of the mononucleotide or dinucleotide markers selected from the group consisting of BAT25, BAT26, D2S123, D5S346, and D17S250.

### Claim 15 (depends on 14)

The method of claim 14, wherein the MSI-positive phenotype is an MSI-high (MSI-H) phenotype characterized by the presence of an MSI at least two of the mononucleotide or dinucleotide markers selected from the group consisting of BAT25, BAT26, D2S123, D5S346, and D17S250.

### Claim 16 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 4-15, wherein the cancer has a mutation that results in a loss of function of ARID1A.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the agent that reduces the level and/or activity of WRN in a cell in the subject is directed to or targets one or more domains of WRN selected from the group consisting of a helicase domain, an endonuclease domain, a RecQ C-terminal domain, and/or a C-terminal helix-turn-helix motif.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the agent that reduces the level and/or activity of WRN is a nuclease, a polynucleotide, a small molecule compound, an antibody, and/or an enzyme.

### Claim 19 (depends on 18)

The method of claim 18, wherein the agent that reduces the level and/or activity of WRN is a nuclease.

### Claim 20 (depends on 19)

The method of claim 19, wherein the nuclease is a clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein.

### Claim 21 (depends on 20)

The method of claim 20, wherein the CRISPR-associated protein is CRISPR-associated protein 9 (Cas9).

### Claim 22 (depends on 19)

The method of claim 19, wherein the nuclease is a transcription activator-like effector nuclease (TALEN), a meganuclease, or a zinc finger nuclease (ZFN).

### Claim 23 (depends on 18)

The method of claim 18, wherein the agent that reduces the level and/or activity of WRN is a polynucleotide.

### Claim 24 (depends on 23)

The method of claim 23, wherein the polynucleotide is an antisense nucleic acid, a CRISPR/Cas 9 nucleotide, a short interfering RNA (siRNA), a short hairpin RNA (shRNA), a micro RNA (miRNA), or a ribozyme.

### Claim 25 (depends on 24)

The method of claim 24, wherein the polynucleotide comprises a sequence having at least 85% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 5-50.

### Claim 26 (depends on 25)

The method of claim 25, wherein the polynucleotide comprises a sequence having at least 85% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 5-10.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the method further comprises administering to the subject an anti-cancer therapy.

### Claim 28 (depends on 27)

The method of claim 27, wherein the anti-cancer therapy is an immunotherapy.

### Claim 29 (depends on 28)

The method of claim 28, wherein the immunotherapy is a CTLA-4 inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, or adoptive T cell transfer therapy.

### Claim 30 (depends on 27)

The method of claim 27, wherein the anti-cancer therapy is a chemotherapy.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the agent that reduces the level and/or of WRN is administered systemically or intratumorally to the subject.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the cancer is an MSI-positive cancer, an MSI-H cancer, an adrenocortical carcinoma, a bladder carcinoma, a breast carcinoma, a cervical squamous cell carcinoma, an endocervical adenocarcinoma, a cholangiocarcinoma, a chronic lymphocytic leukemia, a colorectal cancer, a colon adenocarcinoma, a cutaneous T-cell lymphoma, a lymphoid neoplasm diffuse large B-cell lymphoma, an esophageal carcinoma, a glioblastoma multiforme, a head and neck squamous cell carcinoma, a kidney chromophobe, a kidney renal papillary cell carcinoma, an acute myeloid leukemia, a lower-grade glioma, a liver hepatocellular carcinoma, a lung adenocarcinoma, a lung squamous cell carcinoma, a mesothelioma, a nasopharyngeal carcinoma, an ovarian cancer, an ovarian serous cystadenocarcinoma, a pancreatic adenocarcinoma, a pheochromocytoma, paraganglioma, a prostate adenocarcinoma, a rectal adenocarcinoma, a sarcoma, a skin cutaneous melanoma, a stomach adenocarcinoma, a testicular germ cell tumor, a thyroid carcinoma, a thymoma, an uterine corpus endometrial carcinoma, an uterine carcinosarcoma, an uveal melanoma, a pediatric acute myeloid leukemia, a pediatric neuroblastoma, or a pediatric high-risk Wilms tumor.

### Claim 33 (depends on 32)

The method of claim 32, wherein the cancer is an MSI-positive cancer, an MSI-H cancer, an ovarian cancer, a uterine corpus endometrial carcinoma, a colorectal cancer, a colon adenocarcinoma, or a stomach adenocarcinoma.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the subject is a human.
